ArticleTranslational cancer research2020
KIF4A is a promising prognostic marker and correlates with immune infiltration in clear cell renal cell carcinoma.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway.Clinical and experimental medicine · 2026Article
- KIF4A in disease pathogenesis and therapeutics: from molecular mechanisms to clinical translation.Biology direct · 2025Review
- Kinesin-related genes stratified the prognosis and immune responses of clear cell renal cell carcinoma.European journal of medical research · 2025Article
- Reversal gene expression assessment for drug repurposing, a case study of glioblastoma.Journal of translational medicine · 2025Article
- Reversal Gene Expression Assessment for Drug Repurposing, a Case Study of Glioblastoma.Research square · 2024Article
- CCR8 as a Therapeutic Novel Target: Omics-Integrated Comprehensive Analysis for Systematically Prioritizing Indications.Biomedicines · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKinesin family member 4A (KIF4A) belongs to the kinesin family. It has been found to promote the proliferation and invasion of tumor cells and correlates with the poor prognosis of different types of human cancers. However, the expression and prognostic value of KIF4A in clear cell renal cell carcinoma (ccRCC) and its correlation with tumor-infiltrating immune cells are currently unclear.
methodsHere, we analyzed the expression data of KIF4A in different types of tumors on the TIMER database. The Kaplan-Meier curve was utilized to reveal the correlation between KIF4A expression and the clinical prognosis of ccRCC patients. UALCAN database was utilized to evaluate the relationship between KIF4A expression and the clinicopathological features of ccRCC patients. In addition, the correlation between KIF4A expression and the abundance of immune infiltrates, as well as gene markers of tumor-infiltrating immune cells was determined on the TIMER database.
resultsVarious types of malignant tumors, including kidney renal clear cell carcinoma (KIRC), show high levels of KIF4A expression. The high expression of KIF4A was correlated with the worse prognosis, advanced clinical stage, poorer differentiation, and higher levels of immune infiltration in KIRC.
conclusionsIn summary, KIF4A is a promising prognostic marker and correlates with immune infiltration in clear cell renal cell carcinoma. However, further molecular and cellular experimental evidence is required to validate these conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.